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976Chronic Kidney Disease, Thrombotic Microangiopathy,
and Hypertension Following T Cell-Depleted
Hematopoietic Stem Cell Transplantation
Ilya G. Glezerman,1 Kenar D. Jhaveri,2 Thomas H. Watson,3 Alison M. Edwards,4
Esperanza B. Papadopoulos,5 James W. Young,5 Carlos D. Flombaum,1 Ann A. Jakubowski5Chronic kidney disease (CKD) is now an accepted long-term complication of allogeneic hematopoietic stem
cell transplantation. Calcineurin inhibitors (CNI), which are used for prophylaxis and treatment of graft-
versus-host disease (GVHD), have been associated with the development of nephrotoxicity. Hypertension
(HTN) and thrombotic microangiopathy (TMA) are 2 comorbidities linked to CKD. T cell depletion
(TCD) of stem cell grafts can obviate the need for the use of CNI. We conducted a retrospective analysis
of 100 patients who underwent TCD transplantation: 30 in group A were conditioned without total-body
radiation (TBI) and 70 in group B received a TBI containing regimen. None of the patients received CNI.
The median age was 55.5 and 45 years for groups A and B, respectively. Eleven patients developed TMA,
all in group B. The 2-year cumulative incidence of sustained CKD was 29.2% and 48.8% in group A and group
B, respectively, with a mean follow-up of at least 21 months. CKD free survival was better in the non-TBI
group (P 5 .046). Multivariable survival analysis revealed that exposure to TBI, older age, and TMA were
risk factors for CKD. The incidence of new onset or worsening HTN was 6.7% and 25.7% (P5 .03) in group
A and B, respectively. The use of TBI (P5.0182) and diagnosis of TMA (P5.0006) predisposed patients to the
development of HTN using univariable logistic regression models. Thus, despite the absence of CNI, a pro-
portion of these older patients in both groups developed CKD and HTN.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is widely used in the treatment of hemato-
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6/j.bbmt.2010.02.006undergoingHSCT yearly is only8000 [1], that num-
ber has been increasing, and it is expected to continue
to rise. Long-term survival after transplantation has
improved over the years as a consequence of molecular
human leukocyte antigen (HLA) typing, tailoring
transplantation to particular patient populations and
diseases, improvements in peri-transplant supportive
care, and advancements in infectious disease monitor-
ing and treatment. As the number of HSCT survivors
continues to increase, however, the medical commu-
nity becomes more aware of transplantation-related
health issues that can impact on quality of life and
healthcare costs of these survivors [2,3].
Chronic kidney disease (CKD) is one of the long-
term complications of HSCT that has recently been
addressed in several retrospective studies [4-7].
Although now well recognized, its incidence, etiology,
and clinical course remain controversial. Although it
may develop as a consequence of acute kidney injury
(AKI), it has also been associated with older age,
lower pretreatment glomerular filtration rate (GFR),
female gender, use of total-body irradiation (TBI) and
fludarabine in the conditioning regimen, graft-versus-
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(CNI), and a variety of other factors [4-7].
Hypertension (HTN) has also been recognized as
a late complication of HCST, with incidence of
HTN linked to the development of CKD [5].
A more serious renal complication of transplanta-
tion is thrombotic microangiopathy (TMA). The clin-
ical manifestations of this syndrome include renal
insufficiency, microangiopathic hemolytic anemia
(MAHA), thrombocytopenia, HTN, and in some
cases, neurologic deficits. Unfortunately, controver-
sies in the criteria that define the syndrome have com-
plicated the reporting of its actual incidence [8]. TMA
has also been linked to many similar risk factors as
CKD including older age, female gender, use of TBI,
immunosuppression that includes the use of CNI,
GVHD, and infections. Nevertheless, no specific risk
factor has been consistently supported by available re-
ports in the allogeneic transplantation setting [8].
In appropriately selected patients, T cell-depleted
(TCD) HSCT has similar survival outcomes to those
of unmodified HSCT. TCD of hematopoietic stem
cell (HSC) grafts can obviate the need for CNI as pro-
phylaxis for GVHD. As a consequence, it offers
a unique opportunity to study the effects of TBI and
other risk factors on the incidence of CKD, TMA,
and HTN without the confounding effects of CNI
exposure. Therefore, we retrospectively analyzed the
incidence of CKD, HTN, and TMA in 2 cohorts of
patients transplanted at our center with allogeneic
TCD grafts who were never exposed to CNI. One
cohort of patients was conditioned only with chemo-
therapy, and the second cohort received conditioning
with a TBI containing regimen.PATIENTS AND METHODS
Patients
Data collection and analysis were performed with
the approval of the institutional review board of
Memorial Sloan-Kettering Cancer Center, New
York, NY. Protected health information was coded
in accordance with requirements of Health Insurance
Accountability and Portability Act. Between January
2001 and December 2006, 159 patients underwent
transplantation on 2 protocols utilizing TCD alloge-
neic HSC grafts. Sixty patients received conditioning
with high-dose chemotherapy alone (group A) and
99 patients were conditioned with high-dose chemo-
therapy plus TBI (group B). Patients younger than
18 years of age, those who did not survive beyond
180 days after transplantation or who underwent
second HSCT, and those who received CNI for
treatment of GVHD were excluded from the analysis.
One patient in group B who received sirolimus for
treatment of GVHD was also excluded.Baseline and follow-up demographic, clinical, and
laboratory data were collected on patients by a review
of the medical records. Serum creatinine (SCr) and
blood pressure (BP) measurements were obtained from
0-, 6-, 12-, 18-, and 24-month posttransplantation clinic
visit notes. In addition, each patient recordwas reviewed
in detail for evidence of TMA as described below.
GVHD Evaluation
Acute GVHD (aGVHD) was assessed and graded
according to the criteria of Glucksberg et al. [9] and
modified by Martin et al. [10]. Chronic GVHD
(cGVHD) was diagnosed and graded according to
the criteria of Sullivan et al. [11].
Renal Function, HTN, and TMA Assessment
Renal function at baseline and follow-up was de-
termined by calculating GFR using the Modified
Diet in Renal Disease (MDRD) equation [12]. Severity
of CKD was graded as moderate (stage III) defined as
GFR of\60 mL/min/1.73 m2 and severe (stage IV or
worse) as GFR of\30 mL/min/1.73 m2 according to
Kidney Disease Outcomes Improvement Initiative
[13]. Sustained CKD was a decline of GFR below 60
mL/min/1.73 m2 at least 6 months after HSCT, which
persisted until last follow-up or death. Patients with
pretreatment GFR \60 mL/min/1.73 m2 were ex-
cluded from the study. AKI, which eventually resolved
with a return to baseline kidney function, was not
considered in the analysis.
New cases of HTN were defined in baseline nor-
motensive individuals as the development of sustained
BP .140/90 and/or the need for treatment of HTN
with medication. In patients with HTN at baseline,
worsening HTN was defined as a sustained increase
in BP over baseline levels requiring increased doses
and/or addition of new classes of anti-HTN medica-
tions. Sustained increases were those that were either
observed over at least 3 months or required initiation
of anti-HTN therapy and were still present at last
nonterminal follow-up.
TMA was diagnosed either by kidney biopsy or by
the identification of a clinical syndrome that included
some combination of the following criteria: concomi-
tant development of renal dysfunction, either new or
worsening HTN, evidence of MAHA (based on ane-
mia, schistocytosis, elevated lactate dehydrogenase,
and low haptoglobin levels in the absence of dissemi-
nated intravascular coagulation), and thrombocytope-
nia. Other causes of renal disease were ruled out by
appropriate laboratory and radiologic investigations.
Preparative Regimens, Donors, and Grafts
In group A the chemotherapy regimen consisted of
busulphan 0.8 mg/kg/dose infused intravenously (i.v.)
over 2 hours, every 6 hours for 10 doses at day 29 to
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day27 and26, and fludarabine on day26 to22 at 25
mg/m2/day i.v. infused over 30minutes. Antithymocyte
globulin (ATG), usually rabbit (2.5 mg/kg) and in a few
cases equine (30 mg/kg), were administered on day 23
and22 to all patients. In groupB, the radiation contain-
ing regimen was comprised of hyperfractionated TBI
(HFTBI) followed by thiotepa and fludarabine.HFTBI
was administered in 11 fractions of 125 cGy over 4 day,
to a total dose of 1375 cGy onday29 to26. All patients
had protective lung shielding, and overlying ribs re-
ceived an additional 600 cGy boost. The kidneys were
not shielded.Malepatientswith acute leukemia received
an additional 400 cGy testicular boost in a single frac-
tion. After completion of HFTBI, thiotepa at 5 mg/
kg/day was administered over 4 hours on day 25 and
24 with no adjustment for weight. Fludarabine at 25
mg/m2/day was administered over 30 minutes on day
25 through21.Twodoses of equine (30mg/kg) or rab-
bit (2.5 mg/kg) ATG were administered on the same 2
days as the thiotepa only to patients receiving matched
unrelated or any mismatched graft. The similarity in
the two regimens was the use of equivalent doses of flu-
darabine in both. Differences were thiotepa in the TBI
regimen and busulphan plus melphalan in the all
chemotherapy regimen.
Donors included matched siblings or matched/
mismatched unrelated donors recruited via the
National Marrow Donor Program. Mobilization of
peripheral blood stem cells (PBSC) from donors was
performed by administration of granulocyte colony
stimulating factor (G-CSF) followed by apheresis on
the fifth and, if needed, the sixth days. Selection of
CD341 stem cells was accomplished using the ISO-
LEX 300i Magnetic Cell Separator, followed by sheep
red blood cell (sRBC)-rosette depletion ofT cells. This
method achieved an approximate 5 log10 depletion of
CD31 cells [14]. If bone marrow (BM) was used, based
on donor preference, T cells were removed by sequen-
tial soybean agglutination and sRBC-rosette depletion
[15]. Fresh BM or PBSC grafts were infused through
a central venous catheter 24-48 hours after completion
of conditioning. TCD was the only GVHD prophy-
laxis; no other GVHD prophylaxis was given.
Supportive Care
Patients were managed clinically according to
MSKCC standard guidelines and as previously
described [16]. First-line treatment for GVHD,
when it occurred, was topical steroids (including
budesonide) or systemic steroids.
Biostatistics
Continuous data were compared using a t-test or
theMann-Whitney test for nonnormal data, while cat-
egoric variables were compared using a chi-squaredtest, and, where appropriate, Fisher’s Exact Test.
Average GFR was compared between groups at each
followup time using t-tests. Kaplan-Meier techniques
were used to calculate survival probabilities for the de-
velopment of CKD, and survival curveswere compared
between groups using a log-rank test. To examine the
correlation between outcomes and potential predic-
tors, univariable, and multivariable analyses were
done using Cox proportional hazards models for 2
CKD outcomes (sustained and severe) and logistic re-
gression models for HTN. TBI treatment group and
factors significantly associated with the outcomes in
the univariable analysis were included in the multivari-
able models. Because of the low number of events for
severe CKD, multivariable analysis was not performed
for this outcome. The following parameters were con-
sidered: TBI treatment group, race, age at treatment,
sex, AKI during the first month posttransplantation,
development of GVHD, development of TMA, degree
of HLAmatch, donor type, baseline HTN or diabetes,
and disease. Event times for CKDweremeasured from
date of transplantation to date of death or last contact.
Statistical significance was defined by a P-value less
than .05. All analyses were performed using SAS
software version 9.1 (SAS Institute Inc., Cary, NC).RESULTS
Thirty patients in group A and 70 patients in group
Bwere included in the analysis. Baseline characteristics
of patients in both groups are listed inTable 1. Patients
in groupAwere significantly older (P\.0001), and had
a lower baseline GFR (P 5 .0116). There were differ-
ences in the distribution of diagnoses between the 2
groups (P5 .004). Gender, length of follow-up, preex-
isting comorbidities such as HTN, diabetes mellitus,
and childhood hemolytic uremic syndrome, mis-
matched donors, and incidence of acute GVHD or
chronic GVHD showed no statistically significant
differences between the 2 groups (Table 1).
As illustrated in Figure 1, the mean GFR declined
in both groups over the study period but remained at
or above the 60 mL/min/1.73 m2. Notably, however,
despite a significantly higher mean GFR at baseline
for group B, the mean GFR was lower at the 18- and
24-month follow-up for group B (P 5 .02 and P 5
.052, respectively) compared with that for group A.
The decline in mean GFR between baseline and last
available follow-up was also more significant in group
B 242.0 mL/min/1.73 m2 versus 220.7 mL/min/
1.73 m2 in group A (P 5 .0002). The decline appeared
to plateau between the 18- and 24-month points for
both groups.
Sustained CKD developed in 8 patients in group A
and 32 patients in group B, but this difference was not
statistically significant. Likewise, the proportion of pa-
tients developing severe CKD was not statistically
Table 1. Patient Characteristics.
Group A Group B
N 5 30 N 5 70 p-value
Median age 55.5 45.0 <0.0001
Gender NS†
Male 15 (50.0%) 41 (58.6%)
Female 15 (50.0%) 29 (41.4%)
Diagnosis 0.004
Acute myelogenous leukemia 20 (66.7%) 33 (47.1%)
Acute lymphocytic leukemia 1 (3.3%) 19 (27.1%)
Chronic myelogenous leukemia 0 (0.0%) 7 (10.0%)
Non-Hodgkin’s lymphoma 4 (13.3%) 7 (10.0%)
Myelodysplastic syndrome 5 (16.7%) 4 (5.7%)
Donor-Recipient Match NS
Matched 24 (80.0%) 60 (85.7%)
Mismatched 6 (20.0%) 10 (14.3%)
Donor-Recipient Relationship 0.01
Related 11 (36.7%) 45 (64.3%)
Unrelated 19 (63.3%) 25 (35.7%)
Pre-treatment GFR*(mean) 87.8 (SD‡525.9) 102.3 (SD523.9) 0.012
Other Baseline Co-morbidities
Hypertension 5 (16.7%) 7 (10.0%) NS
Diabetes 0 (0.0%) 2 (2.9%) NS
Childhood hemolytic uremic syndrome 0 (0.0%) 1 (1.4%) NS
Months Follow-up (mean) 21 (SD54.9) 22 (SD54.7) NS
AKI** (first month post transplant) 4 (13.3%) 21 (30.0%) NS
Alive at last follow up 26 (86.7%) 56 (80.0%) NS
Acute GVHD***
Grade 1 2 (6.7%) 4 (5.7%) 0.76943
Grade 2 3 (10.0%) 4 (5.7%)
Grade 3 0 (0.0%) 2 (%2.9)
No Acute GVHD 25 (83.3%) 60 (85.7%)
Chronic GVHD
Extensive 1 (%) 3 (%) 0.23953
Limited 0 (%) 6 (%)
No Chronic GVHD 29 (%) 61 (%)
†Not Statistically Significant.
‡Standard Deviation.
*Glomerular Filtration Rate.
**Acute Kidney Injury.
***Graft versus Host Disease.
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new or worsening HTN was significantly higher in
group B. Comparison of the time to development of
sustained CKD between group A and B is illustrated
by Kaplan-Meier survival curves and indicate signifi-
cant difference in CKD free survival between 2 groups
(Figure 2). Of note and not shown, is the observation
that several patients had GFR\60 mL/min/1.73 m2
at some point during the 2-year period but recovered
to normal renal function at last follow-up, although
no patient who progressed to severe CKD recovered.
Univariable analyses conducted to determine the
effects of patient characteristics suggest that age (P 5
.032) and TMA (P 5 .0068) predicted development of
sustainedCKD.The only significant predictor of severe
CKDwasTMA (P\ .0001). Both treatment in theTBI
group and development of TMA predicted develop-
ment of HTN (P5 .0182 and P5 .0006, respectively).
The multivariable model predicting sustained
CKD suggested that treatment with TBI (group
B versus A, P 5 .0286)), age at transplant (P 5 .001),and development of TMA (P 5 .0012) were signifi-
cantly associated with the outcome. The risk of devel-
oping sustained CKD is 2.71 (95% confidence
interval [CI]: 1.11, 6.60) times higher for the patients
receivingTBI (group B) than the patients not receiving
TBI (group A). The hazard ratio (HR) for age was 1.05
(95%CI: 1.02, 1.09)with a 1-year increase in a patient’s
age raising his/her risk of developingCKDby 5%.The
hazard ratio for TMA was 4.27 (95% CI: 1.78, 10.24),
with the risk of developing CKD 4.3 times higher for
patients with TMA than for patients without TMA.
Donor status was considered as the fourth and final
variable in the multivariable model but did not signifi-
cantly predict the development of CKD.
The cumulative incidence probability at 2 years for
development of sustained CKD was 29.2% (95% CI:
15.7, 50.2) for group A and 48.8% (95% CI: 37.4,
61.6) for group B. Similarly, the cumulative incidence
probability of severe CKD was 6.5% (95% CI: 1.7,
23.5) for group A and 12.8% (95% CI: 6.6, 24.0) for
group B.
Figure 1. Comparison of mean glomerular filtration rate between two groups during 2-year follow-up. *Total-body irradiation; **glomerular filtration rate.
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of TMA were included in the multivariable logistic re-
gression model for the development of HTN. After
adjusting for treatment group, patients with TMA
were 9.0 times more likely to have HTN than patients
without TMA (95% CI: 2.2, 39.84; P 5 .0025).
Eleven patients developed TMA in group B,
whereas none were identified in group A (p 5 .031).
The clinical findings of TMA are summarized in
Table 2. The mean time of onset of CKD and signs
of hemolysis were 11 months posttransplantation
with a range of 6 to 20 months. Seven of these patients
developed new or worsening HTN and 3 developed
edema. Renal dysfunction of varying degrees was pres-
ent in all of these patients and 1 patient progressed to
end-stage renal disease (ESRD) requiring dialysis 30
months after HSCT. Patient 2 (Table 2) had a normal
SCr 1.3 mg/dL (0.6-1.3 mg/dL) at the time of diagno-
sis but it was increased from the patient’s baseline of
0.8 mg/dL. Four patients underwent kidney biopsy
to confirm the diagnosis of TMA. All biopsies showed
glomerular capillary wall thickening and basement
membrane double contours, as well as other features
characteristic of TMA. Seven of the 11 patients with
TMA survived and were evaluated at 24 months. The
mean GFR in these patients was 41 mL/min/1.73
m2. Additionally, patient 11 (Table 2) was known to
be alive at 24months but did not have blood work eval-
uation recorded at our center beyond 18 months. At
that time the GFR was 24 mL/min/1.732.Figure 2. Kaplan-Meier estimate of sustained CKD free survival.
*Total-body irradiation; **chronic kidney disease.DISCUSSION
The cumulative incidence in HSCT patients for
development of moderate and severe CKD has been
reported to be 12% to 29% and 3% to 3.6%, respec-tively, in retrospective cohort analyses [4-6]. These
rates are markedly higher than those observed in the
general population of 4.3% and 0.2%, respectively
[13]. Furthermore, the incidence of ESRD was also
reported to be 16 times higher than that in an age-
matched population [17]. Renal function also has
been shown to decline significantly following HSCT,
even if patients do not develop overt CKD. In that re-
gard,Weiss et al. [18] described a.25% decline in the
renal function of 66% of patients who underwent
a nonmyeloablative HSCT, which included low-dose
TBI and CNI prophylaxis for GVHD. A variety of
risk factors have been associated with the renal compli-
cations of HSCT, including the use of CNI and TBI
[4,7]. Our analysis of the 2 groups of patients who
underwent TCD transplantation without the
administration of CNI afforded the opportunity to
assess the impact of TBI alone on renal function
after HSCT.
Table 2. Clinical Features of Patients with Thrombotic Microangiopathy
Pt1 No
Time of
onset (month) Haptoglobin LDH2 Schistocytes Plt3 Hgb4 Creat5 Proteinuria Hematuria
Kidney
Biopsy Comments
1 12 <6 376 no 157 8.8 2.1 yes yes yes new HTN6
2 8 <6 391 no 15 5.8 1.3 yes yes (-)7 indirect Coombs
3 12 36 227 no 83 7.7 1.7 yes yes yes
4 9 not done 309 yes 48 9.2 2.4 yes yes new HTN
5 12 42 212 no 137 11.8 1.5 yes no worsening HTN
6 14 62 268 no 223 9.4 2.6 no no yes ESRD8
7 12 <6 303 no 113 10.8 2.4 yes no new HTN
8 20 315 459 not done 126 9.7 2.3 yes no new HTN
9 7 <6 220 no 106 9.2 1.7 yes yes new HTN; edema
10 10 <6 501 yes 84 8.2 1.6 yes yes edema
11 6 <6 400 yes 72 10.6 1.5 yes yes yes edema; new HTN
1Patients.
2Lactade Dehydrogenase (normal range: 60-200Units/L).
3Platelets (normal range: 160-400K/mcL).
4Hemoglobin (normal range: 13-17g/dl in males and 11.5-16g/dl in females).
5Creatinine (normal range: 0.6-1.3mg/dl).
6Hypertension.
7Negative.
8End Stage Renal Disease.
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both patient groups. The greater decline, however,
occurred in the patients treated with TBI, group B. In-
terestingly, this group was comprised of younger pa-
tients, median age 45.0 years versus 56.5 years (for
group A), who had significantly higher baseline
GFRs. Because both groups received similar dosing
of fludarabine, and thiotepa is not considered a nephro-
toxin, this finding supports an adverse effect of radia-
tion therapy, even when the TBI is administered
using hyperfractionation, albeit without kidney shield-
ing. Our patients in group B all received a dose of 1375
cGy, which falls within the range previously associated
with an increased risk of posttransplantation renal
dysfunction. Miralbell et al. [7] described a dose-
dependent increase in the incidence of renal dysfunc-
tion at 18 months post-TCD transplantation, with
a 52% incidence for patients who received 1350 cGy
TBI. Although the patients in that study received
short-term cyclosporine prophylaxis posttransplanta-
tion, their median age was only 32.5 years. The
2-year cumulative incidence of sustained CKD of
48.8% (group B) versus 29.2% (group A) and of severe
CKD of 12.8% (group B) and 6.5% (group A), con-
firms a greater nephrotoxic effect in the group that
received TBI versus the group that received only che-
motherapy. Additionally, Kaplan-Meier analysis dem-
onstrated a statistically significant difference in the
development of sustained CKD between the 2 groups,
and multivariable analysis showed that TBI is a risk
factor for the development of CKD, after adjusting
for age and TMA.
Despite the absence of CNI in the treatment regi-
mens, both groups of patients in this analysis had
a higher incidence of sustained and severe CKD than
reported by a number of other investigations [4-6].This supports the contribution of other clinical
factors. TCD is an especially attractive modality for
older patients undergoing transplantation because of
the reduced incidence of GVHD. Patients normally
experience some decline in renal function with aging,
which can be compounded by comorbidities and
medications. Delgado et al. [5] previously reported
on 3 groups of patients receiving TBI and TCD grafts.
Risk factors strongly predicting for CKD were age
at transplantation, \30 years versus $30 years (HR
5 6.58) and the presence of fludarabine in the
conditioning regimen (HR 5 2.57). The median age
of patients in the 3 groups were 27, 30, and 38.5 years.
Furthermore, a recent report showed that 69% of
patients who developed CKD after HSCT were older
then 40 years of age. Older age was confirmed to be
a risk factor for the development of sustained CKD
in this study as well. Patients in group A were signifi-
cantly older than patients in group B and overall the
median age in both groups (55.5 and 45.0 years) was
significantly higher than that in previously reported
cohorts receiving similar conditioning regimens.
This may also explain why the incidence of sustained
CKD was not statistically different in the 2 groups.
After adjusting for treatment group, a 1-year increase
in a patient’s age at the time of transplantation resulted
in a 5% increased risk of CKD. This is contrasted to
only a 8% decline in GFR of healthy individuals
with each decade of life beginning at age 30 [19].
AKI in the early posttransplantation period, female
gender, GVHD, and fludarabine have been reported as
risk factors for CKD following HCST [4-6]. The
current study was unable to analyze fludarabine as
a risk factor because patients in both cohorts received
this agent as part of their conditioning. Therefore,
a contribution of fludarabine to the higher incidence
982 Biol Blood Marrow Transplant 16:976-984, 2010I. G. Glezerman et al.ofCKD inboth groupsor an additive effect to that of the
TBI cannot be excluded. Melphalan, used in the
conditioning regimen of group A, has been reported to
cause AKI in patients undergoing autologous PBSCT
for treatment of systemic amyloidosis [20]. Patients
who developed AKI in that study were more likely to
progress to ESRD. Notably, patients had baseline pro-
teinuria in the nephrotic range and low baseline GFRs,
indicating significant underlying renal pathology. It is
therefore difficult to assess the true impact of the mel-
phalan on the development of CKD. Although the cur-
rent study cannot exclude a contributionofmelphalan to
the overall outcome inCKD for patients in group A, the
incidence of AKI was low in that group and AKI was
shown not to be a predictor of poor renal outcomes. In
the univariable analysis neither gender nor AKI in the
firstmonth after transplantationwere found tobe signif-
icant risk factors for CKD. GVHD also did not predict
development ofCKD.This findingmaybe confounded,
however, by the exclusion of patients with higher grade
GVHD requiring treatment with CNI.
TMA has been recognized as one of the causes of
CKD in HSCT patients. Histologic features of post-
HSCT TMA in the kidneys have been well described
[21]. In a classic review by Pettitt and Clark, TMA
following transplantation was divided into 4 distinct
but overlapping subtypes based on association, clinical
presentation and prognosis [22]. The first type, called
‘‘multifactorial fulminant TMA,’’ occurs in the first
100 days in patients receiving CNI for active GVHD,
patients developing CMV infection and following
intensive pretransplant conditioning. This diagnosis
carries a poor prognosis. The second type, ‘‘condition-
ing related TMA,’’ includes patients who develop TMA
later in the clinical course, around 6 months after trans-
plantation. In most patients the conditioning regimen
includes TBI. The remaining 2 subtypes are strongly
associated with CNI use and manifest either as
nephrotoxicity or neurotoxicity of these agents.
In this study, all cases of TMA occurred in patients
in group B, supporting an association with the use of
TBI. Time of presentation and clinical course of
patients with TMA was consistent with the ‘‘condi-
tioning-related’’ type. Interestingly, only 3 patients
had schistocytes on peripheral smear, and haptoglobin
was normal in 4 patients. Furthermore, LDHwas only
mildly elevated in this group with a mean value of 333
(60-200) U/L. Two patients with kidney biopsy find-
ings of TMA had a normal haptoglobin and no schis-
tocytes. This lack of some of the clinical criteria
usually employed to make a diagnosis of TMA, espe-
cially in the absence of renal biopsies, could account
for a lower incidence reported in some previous studies
and a higher incidence in this study. This phenomenon
of isolated renal involvement, however, has been
described in both non-HSCT and HSCT patients
with secondary TMA [23-25].In recent years, 2 consensus statements have been
published in an effort to define clinical features and di-
agnostic criteria of posttransplantation TMA. Unfor-
tunately, even these 2 expert panels did not agree on
all of the criteria. Presence of schistocytes on periph-
eral smear, elevated LDH level, concurrent renal
and/or neurologic dysfunction, and negative direct
and indirect Coombs test have been selected as diag-
nostic criteria for TMA by the Blood and Marrow
Transplant Clinical Trials Network Toxicity Com-
mittee [26]. The International Working Group’s
(IWG-an initiative of the European Group for Blood
and Marrow Transplantation and the European
LeukemiaNet) definition of transplant-associated
microangiopathy (TAM) includes the presence of
schistocytes, thrombocytopenia, increased LDH level,
decrease in hemoglobin concentration, or increased
red blood cell transfusion requirement and decrease
in serum haptoglobin [27]. Interestingly, neither
group addressed the Pettit et al. [28] categorization
of time posttransplantation to development of TMA.
Thus, the criteria remain variable and pathologic
findings on kidney biopsy may be present despite the
absence of some of the clinical criteria. As observed
in this study, only 1 of 4 patients, who had a positive
kidney biopsy, satisfied all diagnostic criteria of the
IWG consensus. Identifying other signs that are com-
mon in patients with TMA may assist in diagnosing
this condition. The majority of patients with TMA
in this study demonstrated proteinuria, hypertension,
and renal dysfunction. In a recent case cohort TMA
syndrome was characterized by hypertension, renal
dysfunction, and anemia. Therefore, new or worsening
hypertension, edema, proteinuria, and renal dysfunc-
tion may characterize patients developing late TMA
even if the hematologic findings of MAHA are absent.
The importance of recognizing TMA as a late
complication of HCST was underscored by the fact
that TMAwas the only risk factor identified in univari-
able analysis to be associated with development of
severe CKD. It was also identified as a risk factor for
development of new or worsening HTN in multivari-
able analysis. Because HTN and CKD are significant
comorbidities as well as risk factors for heart disease,
even a more indolent form of TMA may impact on
long-term mortality of patients undergoing HSCT.
HTN has been reported as a complication of
HSCT and has been associated with the development
of CKD [5]. In our study, HTN was strongly associ-
ated with exposure to TBI and development of
TMA, and not to other potential risk factors that
were evaluated.
Finally, of concern is the higher overall incidence
of sustained and severe CKD observed in this study
compared to previous reports. We propose a few
potential explanations. First, the population of patients
in both groups was older in this study than in the
Biol Blood Marrow Transplant 16:976-984, 2010 983Kidney Disease in Allogeneic Hematopoietic Stem Cell Transplantationprevious reports. We and others have confirmed the
impact of age at transplantation on the incidence of
CKD and the accelerated deterioration above that re-
ported for the natural aging process. Second, criteria
for diagnosing CKD have been variable across many
published reports. Some studies have utilized an in-
crease in SCr above normal for the diagnosis of
CKD. This can lead to an underestimation of the diag-
nosis in patients with reduced muscle mass such as
older individuals and those debilitated by previous
chemotherapy. Third, a medication or treatment
common to both groups, such as fludarabine, antithy-
mocyte globulin, or 1 of the prophylactic medications
routinely used could have contributed to the age and
TBI components.
Recently available data also supports our findings
of high incidence of CKD after HSCT. In a cohort
of 100 patients who underwent myeloablative alloge-
neic HSCT and survived for .100 days the incidence
of CKD, defined as GFR\60mL/min/1.73 m2 lasting
for .3 months, was 64%. The risks for the develop-
ment of CKD in this group were ARF within 100
days after HSCT and age .40 years [29].
Regardless of the specific etiologies, however, this
study reflects the transplantation community’s contin-
ued interest in addressing the growing population of
over 40 year olds who are undergoing HSCT and
developing new medical and psychosocial issues. Mye-
lodysplastic syndrome/secondary acute myelogenous
leukemia (AML) and non-Hodgkin’s lymphoma
(NHL) are diseases of older patients. Physicians have
a better understanding of the lack of curability of
patients with these diseases with chemotherapy alone
and are now expanding the application of transplanta-
tion and referring more patients with these diagnoses.
In most of the patients in this study with sustained
CKD there was no impact on quality of life related
to the condition. It remains to be seen whether CKD
becomes a greater issue in healthcare as these patients
age, acquire additional comorbidities that impact on
renal function, or require treatments that can nega-
tively impact renal function. For the present, these
findings support the development of clinical trials to
proactively reduce renal damage in HSCT.ACKNOWLEDGMENTS
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